EMBRYOTROPIC PROPERTIES OF A NEW COMPOSITION OF FENBENDAZOLE AND ALBENDAZOLE (PANAVERM PLUS)

The drug Panaverm plus administered at the doses of 10,0; 15,0; 25,0; 35,0 and 45,0 mg/kg body weight (by 4.5 times increased dose) showed no embryotropic activity. Panaverm plus used at the dose of 55,0 mg / kg body weight did not cause changes in the development of embryos, except one case of hydrocephaly and reduction of embryo weight. Objective of research: studies of the embryotropic properties of preparation Panaverm plus. Materials and methods: The studies of embryotropic properties of preparation Panaverm plus were conducted on 40 outbreed white female rats with weight 200-250 g. in accordance with «Methodical recommendations for estimation of drug effects on reproductive function of animals» approved by Ministry of Healthcare of the Russian Federation (1997). Results and conclusion: Panaverm plus administered at the doses of 10,0; 15,0; 25,0; 35,0 and 45,0 mg/kg body weight (by 4.5 times increased dose) showed no embryotropic activity. Panaverm plus used at the dose of 55,0 mg / kg body weight did not cause changes in the development of embryos, except one case of hydrocephaly and reduction of embryo weight